---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-029721"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2025-09-23T23:59:59+00:00"
generated_at: "2026-05-17T05:52:09.633363+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025

## Summary
- Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.
- Q4 net revenue $15.1M (+4% YoY); net loss $19.8M vs $4.6M prior year (incl. $18.1M impairment and derivative losses).
- ADHD Portfolio net revenue $57.6M (flat YoY); Pediatric Portfolio $8.8M (+20% YoY).
- Cash $31.0M at June 30, 2025; 9th consecutive quarter of positive adjusted EBITDA.
- EXXUA (gepirone) for MDD launch on track for Q4 2025; entering >$22B US MDD market with novel first-in-class agent.

## SEC filing metadata
- accession: 0001437749-25-029721
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2025-09-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774925029721/0001437749-25-029721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774925029721/aytu20250514_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-029721
- JSON: https://secwatch.observer/filing/0001437749-25-029721.json
- Plain text: https://secwatch.observer/filing/0001437749-25-029721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.